Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -109.18% | -94.09% | 537.17% | -1.65% | -92.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -109.18% | -94.09% | 537.17% | -1.65% | -92.47% |
| Cost of Revenue | -30.43% | -12.32% | -28.80% | -48.79% | -75.78% |
| Gross Profit | -51.08% | -70.72% | 265.83% | 70.85% | -118.73% |
| SG&A Expenses | -56.62% | -0.79% | 15.10% | 55.40% | -28.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.56% | -8.43% | -17.58% | -24.39% | -63.75% |
| Operating Income | 21.26% | -34.52% | 173.81% | 31.73% | -222.56% |
| Income Before Tax | 94.93% | -168.64% | 221.51% | -162.31% | -592.19% |
| Income Tax Expenses | 101.51% | -- | -- | -- | -3,019.87% |
| Earnings from Continuing Operations | 94.23% | -168.64% | 221.51% | -162.31% | -537.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.23% | -168.64% | 221.51% | -162.31% | -537.96% |
| EBIT | 21.26% | -34.52% | 173.81% | 31.73% | -222.56% |
| EBITDA | 22.39% | -34.27% | 175.58% | 31.97% | -214.28% |
| EPS Basic | 99.01% | 35.44% | 125.86% | -129.31% | -- |
| Normalized Basic EPS | 97.82% | 75.75% | 130.45% | 27.11% | -- |
| EPS Diluted | 98.98% | 35.44% | 124.22% | -129.31% | -- |
| Normalized Diluted EPS | 97.82% | 75.75% | 128.62% | 27.11% | -- |
| Average Basic Shares Outstanding | 380.19% | 316.10% | 226.97% | 5.92% | -- |
| Average Diluted Shares Outstanding | 380.19% | 316.10% | 247.84% | 5.92% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |